Background
==========

Congenital hypothyroidism (CH) is the commonest neonatal endocrine disorder, (incidence 1:1500 in Europe) and a national UK screening programme enables prompt diagnosis and initiation of levothyroxine treatment ([@bib1]). Dyshormonogenesis, in which there is inadequate thyroid hormone biosynthesis due to a specific defect in one of the protein components of the thyroid hormone biosynthetic machinery, usually arises due to mutations in the following genes: *TG*, *TPO*, *DUOX2*, *DUOXA2*, *IYD*, *SLC26A4* and *SLC5A5*. European Society for Paediatric Endocrinology (ESPE) guidelines recommend genetic counselling in such cases, although we have observed interregional variability in the proportion of cases undergoing molecular genetic ascertainment in the UK ([@bib2]).

Significant fetal hypothyroid goitre is a rare conse­quence of fetal dyshormonogenesis, and complications include polyhydramnios due to oesophageal compression and malpresentation due to neck hyperextension at delivery; additionally, neonatal tracheal compression may cause fatal respiratory compromise ([@bib3], [@bib4]). The infrequent occurrence of non-autoimmune fetal hypothyroid goitre and the risks associated with intrauterine diagnosis and therapy have precluded large-scale studies of optimal treatment. Intraamniotic T4 may be beneficial in reducing goitre size however in the UK, parenteral T4 is not readily available, and there is one reported UK case in which intraamniotic T3 administered prior to T4 initiation achieved a successful outcome. The optimal dosing regimen for either drug remains to be ascertained ([@bib2], [@bib4], [@bib5]).

We describe the second case of hypothyroid fetal goitre to be treated with intraamniotic T3 injection whilst T4 was being sourced, and the resulting intrauterine death which highlights the fetal compromise which may occur in this context. Genetic ascertainment in the surviving sibling with dyshormonogenic CH showed that compound heterozygous *TG* mutations were the likely aetiology for the fetal presentation, enabling appropriate genetic counselling to be initiated.

Case presentation
=================

A male infant ([Fig. 1](#fig1){ref-type="fig"}: P1) weighing 3.58 kg was born at term to non-consanguineous, euthyroid Indian parents after an uncomplicated pregnancy. Following an instrumental delivery, he required resuscitation (Apgar scores were 5 (1 min) and 7 (5 min)) and sustained a depressed frontal bone and left sided facial nerve palsy due to birth trauma, which were conservatively managed. Neonatal screening revealed CH (fT4: 7 pmol/L normal range (NR): 9.0--25.0), Thyroid-stimulating hormone (TSH) \>100 mU/L (NR: 0.3--5.0)), and a subsequent isotope scan demonstrated appropriate uptake in a normally-sited thyroid gland ([Fig. 2](#fig2){ref-type="fig"}). He had prolonged jaundice but was otherwise healthy and prompt initiation of levothyroxine treatment has enabled normal growth and development. Figure 1Pedigree diagram for the affected family. Black bars denote those individuals who have been genotyped; black and grey shading denotes confirmed (P1) and presumed (P2) compound heterozygous genoypes, heterozygotes for one of the two mutations are denoted by a central black dot. Figure 2Technetium-99m pertechnetate thyroid scintigraphy performed in P1 aged 29 days, demonstrating appropriate radionuclide uptake in a normally-sited thyroid gland, consistent with dyshormonogenesis. (A) Anterior and (B) lateral images.

There was no family history of thyroid disease however his mother exhibited congenital shortened right limbs; his father was well and had fathered 4 healthy children in a previous relationship ([Fig. 1](#fig1){ref-type="fig"}). They went on to have a second pregnancy complicated by a fetal goitre detected on routine ultrasound ([Fig. 3](#fig3){ref-type="fig"}). Figure 3Sequential fetal ultrasound images with gestational age annotated demonstrating progressive fetal goitre (white arrow). A coronal view at 23 + 3 weeks gestation demonstrates a goitre measuring 42.8 mm × 26.6 mm which persists aged 24 + 4 weeks (sagittal view) and has enlarged to 54 mm × 36 mm × 52 mm aged 29 + 2 weeks gestation (sagittal view), 48 h prior to intrauterine liothyronine therapy.

Investigation
=============

During the second pregnancy, a 20-week obstetric scan revealed a fetal thyroid goitre which continued to enlarge between 23 + 3 and 29 + 2 weeks, with associated polyhydramnios ([Fig. 3](#fig3){ref-type="fig"}). Maternal biochemistry confirmed euthyroidism (TSH: 3.2 mIU/L; NR: 0.3--5.0) with absent autoantibodies (TPO \<20 IU/mL; NR: 0--60), and amniotic fluid TSH measurements at 29 + 4 weeks were consistent with fetal hypothyroidism*:* TSH: 1.5 mIU/L (NR \<0.51).

Treatment
=========

The large hypothyroid fetal goitre and polyhydramnios supported a diagnosis of fetal dyshormonogenesis with obstructive dysphagia, due to local oesophageal compression. A decision was made to commence intraamniotic thyroid hormone replacement, initially by injection of 120 µg T3 at 29 + 4 weeks with concomitant amniocentesis (260 mL). T3 was selected in the first instance due to the fact that we encountered difficulties sourcing parenteral T4 in the UK and the requirement for local approval to be granted prior to its administration would have resulted in significant treatment delay had we opted for first-line T4 therapy. At 31 weeks gestation, considerable polyhydramnios and fetal hypothyroidism persisted (amniotic TSH: 5.3 mIU/L (NR \<0.51), compared with TSH 1.5 mIU/L at 29 + 4 weeks) therefore 150 µg intraamniotic T4 was administered following further amniocentesis having been sourced and locally approved in the interim.

Outcome and follow-up
=====================

At 31 + 3 weeks gestation, an obstetric scan was performed for reduced fetal movements, which revealed an intrauterine death in association with significant polyhydramnios including accumulation of amniotic fluid in the extraamniotic/subchorionic space. The stillborn infant (P2) was male, weighing 1.62 kg, with a normal male karyotype on amniotic fluid analysis. There was no evidence of intrauterine infection and postmortem was declined.

Although DNA was not extracted from the fetus, the history of CH in the elder sibling prompted genetic screening of *TPO* (thyroid peroxidase) and *TG* (thyroglobulin). Compound heterozygous *TG* mutations were identified, comprising a novel, paternally-inherited single nucleotide deletion (c.5178delT, p.A1727Hfs\*26), and a maternally-inherited missense mutation (c.7123G \> A, p.G2375R), which has been previously reported in association with CH without fetal goitre ([@bib6]) [Fig. 4](#fig4){ref-type="fig"}). Figure 4Sequencing electropherograms from the proband (P1), mother and father, illustrating compound heterozygous *TG* mutations, comprising a novel, paternally-inherited single nucleotide deletion (c.5178delT, p.A1727Hfs\*26), and a maternally-inherited missense mutation (c.7123G \> A, p.G2375R).

Discussion
==========

Although biallelic *TG* mutations commonly underlie CH due to dyshormonogenesis, their absolute frequency is low, and fetal goitre is a rare complication which may be associated with significant morbidity ([@bib3], [@bib7], [@bib8]). The proband in this family harboured compound heteroygous *TG* mutations, and although the stillborn fetus was not genotyped, his goitrous hypothyroidism *in utero* supports an identical genetic diagnosis. Although the proband did not have goitre, he exhibited biochemically moderate-severe CH at diagnosis, and such phenotype variability occurs in other kindreds harbouring *TG* mutations. The phenotypic modulators remain uncharacterized although dietary iodine intake, (not quantified here), may be implicated ([@bib9]).

ESPE guidelines recommend genetic counselling in patients with dyshormonogenetic CH, since most patients have an underlying genetic basis. Fetal goitre has been reported in association with *TG* and *TPO* mutations however both discordance and recurrence in successive pregnancies has been documented ([@bib2], [@bib3], [@bib10]). A genetic diagnosis in the kindred enabled us to counsel the parents that future offspring had a 25% probability of inheriting biallelic mutations and developing CH with a consequent risk of fetal goitre. In subsequent pregnancies, prenatal genetic diagnosis could facilitate management by mandating stringent surveillance for fetal goitre, and optimization of maternal iodine status. Additionally, given the practical difficulties in obtaining parenteral T4 in the UK, this could be pre-emptively acquired in the event of a positive genetic diagnosis in the fetus, in case intraamniotic T4 therapy became necessary.

Management of hypothyroid fetal goitre remains controversial, as there are significant risks associated with both diagnostic amniocentesis/cordocentesis and intraamniotic thyroid hormone therapy including miscarriage. Although cordocentesis is the gold standard for assessment of fetal thyroid status, we felt the clinical likelihood of fetal hypothyroidism was high (euthyroid mother, negative autoantibodies and brother with CH), and therefore measured amniotic fluid thyroid hormone levels since this could be achieved simultaneously with therapeutic amniocentesis and intraamniotic injection ([@bib2], [@bib7]).

Treatment of fetal hypothyroid goitre requires optimization of maternal thyroid status including minimizing doses of antithyroid drugs, followed by either conservative management with neonatal levothyroxine administration, or direct fetal treatment in utero with thyroid hormone, since the placenta is not readily permeable to maternally-administered thyroxine or liothyronine ([@bib8], [@bib11]). Fetal hypothyroid dyshormonogenic goitre in the context of maternal euthyroidism has been managed successfully with radiological surveillance, followed by elective delivery and neonatal levothyroxine treatment, especially in cases presenting at late gestational ages. However intubation and ventilation may be required to support neonatal respiratory compromise at birth, and concerns regarding dystocia may necessitate Caesarean section. MRI may be more effective than ultrasound in assessing the degree of tracheal compression ([@bib8], [@bib12], [@bib13]).

Cases treated in utero have usually been given intraamniotic levothyroxine, for which one retrospective cohort study supports a beneficial effect in reducing goitre size. Intraamniotic T3 (three injections of 60, 60 and 120 µg at 30 + 5--32 + 3 weeks) prior to T4 initiation has also been used successfully in another UK case. Treatment response is assessed by monitoring goitre size and resolution of polyhydramnios, sometimes in addition to sequential fetal thyroid hormone measurements. 3D ultrasonography may prove a superior tool to standard techniques in monitoring fetal goitre size in the future ([@bib3], [@bib2], [@bib4], [@bib14]). The optimal dosing regimen for intraamniotic therapy and effect on neonatal thyroid hormone status remains undefined, and associated complications include premature delivery, intrauterine infection and death. Published records describe preterm labour and chorioamnionitis following intraamniotic T4, and a case of fetal death is alluded to in one report (8, summarized in (15)). In view of these caveats, intraamniotic therapy is generally considered only when there is progressive hydramnios or likely tracheal occlusion, although conservative management in this context may also be associated with preterm delivery and neonatal death ([@bib3], [@bib7], [@bib3], [@bib15]).

In our patient, logistical barriers (sourcing parenteral T4 in the UK, obtaining local approval for therapy) initially precluded the use of intraamniotic T4. However worsening polyhydramnios compelled us to administer an intraamniotic injection of the active thyroid hormone T3 (which has a shorter half-life and greater potency than T4) until parenteral T4 became available. Treatment with intraamniotic T4 would have been preferable to T3, which will cause more precipitous fluctuations in hormone levels and has only one case report to support its use. The precise cause for the intrauterine death in our case was undertermined, although significant polyhydramnios with extension into the extraamniotic/subchorionic space was observed and is likely to have played a major role. Additionally, although there was no evidence of intrauterine infection, the treatment itself may have contributed to fetal demise, given the known risk of fetal loss associated with amniocentesis and the short time interval between intraamniotic injection and intrauterine death. At 31 weeks gestation, we selected a dose of intraamniotic T4 similar to that used in the previous intraamniotic T3/T4 combination therapy report (150 µg) however others have reported successful outcomes with higher doses of T4 alone (200--400 µg at similar gestational age), raising the possibility this dose was insufficient ([@bib4], [@bib5]). Dysphagia due to tracheo-oesophageal compression may also have impaired the ability of the fetus to ingest intraamniotic medication such that that earlier initiation of thyroid hormone therapy may have been more effective ([@bib5]).

Difficulties in obtaining parenteral T4 in the UK compound management of fetal goitrous hypothyroidism and our case emphasizes the requirement for further studies before T3 is considered a suitable therapeutic alternative. Additionally, our report highlights the morbidity and mortality associated with hypothyroid fetal goitre and its intrauterine treatment, which may be obscured in the literature due to a tendency for under-reporting adverse outcomes in similar complex cases ([@bib8]). Although not universally undertaken, genetic ascertainment in such families may help predict risk of recurrence in future pregnancies and guide antenatal management.
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